Alnylam Pharmaceuticals Inc (ALNY)
ALNY · Health Care · 
United States
Alnylam Pharmaceuticals Inc (ALNY) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 0.35%. Anyone who holds an ETF containing Alnylam Pharmaceuticals Inc also has an indirect stake in the company.
Data and Charts: Alnylam Pharmaceuticals Inc
Key Data for Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Stock Price Chart
The Alnylam Pharmaceuticals Inc chart shows daily closing prices and is set to the current year by default. The stock is down 58.5% year to date and down 63.3% over twelve months. The last recorded close on October 30, 2026, was $165.00, at 0% of the 52-week range.
Price series from our database since Aug 12, 2024, 558 daily values.
Alnylam Pharmaceuticals Inc Stock Performance
| Year to date | -58.5% | 1 year | -63.3% |
|---|---|---|---|
| 1 month | -33.1% | 3 months | -19.7% |
| Calendar year 2025 | +69.0% |
Measured in euros, Alnylam Pharmaceuticals Inc is down 56.4% year to date and down 62.1% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: Alnylam Pharmaceuticals Inc
What ETF Is Alnylam Pharmaceuticals Inc In?
Alnylam Pharmaceuticals Inc has above-average ETF coverage and is held by 21 of the 104 ETFs we track, which together follow 10 indices. That puts the stock in more ETFs than 83.5% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XUHL / XUHC | MSCI USA Health Care | 0.35% | €3.45 |
| XDWH | MSCI World Health Care | 0.26% | €2.56 |
| SPFS | MSCI World Health Care | 0.24% | €2.42 |
| XDEB | MSCI World Minimum Volatility | 0.12% | €1.17 |
| XNAS / XNA1 | Nasdaq 100 | 0.10% | €1.01 |
| EXXT | Nasdaq 100 | 0.10% | €1.00 |
| 2B7K | MSCI World SRI | 0.10% | €1.00 |
| XD9U / XD9D | MSCI USA | 0.03% | €0.35 |
| SPYI / SPSA | MSCI ACWI IMI | 0.03% | €0.27 |
| XDWD / XDWL | MSCI World | 0.03% | €0.26 |
| SWWD | MSCI World | 0.02% | €0.23 |
| SPPW | MSCI World | 0.02% | €0.23 |
| WIMI | MSCI World IMI | 0.02% | €0.23 |
| SPYY | MSCI ACWI | 0.02% | €0.22 |
| EUNL | MSCI World | 0.02% | €0.20 |
| IUSQ | MSCI ACWI | 0.02% | €0.20 |
The last column shows how much of €1,000 in one of these funds goes to Alnylam Pharmaceuticals Inc, based on each fund's latest holdings list.
US-listed ETFs holding Alnylam Pharmaceuticals Inc (weight per latest SEC filing): QQQ 0.17%, QQQM 0.14%, VUG 0.13%, ONEQ 0.07%, VTI 0.06%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
Alnylam Pharmaceuticals Inc Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), Alnylam Pharmaceuticals Inc had a weight of 0.02% on Sep 30, 2019 and 0.02% on Oct 30, 2026. The fund tracks the MSCI World. Its share peaked at 0.07% on Sep 30, 2025. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Alnylam Pharmaceuticals Inc overlaps with the rest of a portfolio.
Which Tracked Investors Hold Alnylam Pharmaceuticals Inc?
Alnylam Pharmaceuticals Inc is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. The only manager we track that holds Alnylam Pharmaceuticals Inc reduced its position.
| Investor | Shares | Value | Quarter |
|---|---|---|---|
| Bridgewater Associates | 99,584 | $30M | reduced by 7,008 |
As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.
What Alnylam Pharmaceuticals Inc Executives and Directors Traded Recently
| Date | Person | Type | Shares | Price |
|---|---|---|---|---|
| Oct 2, 2026 | SUPRAN BRYAN Officer, EVP, CLO and Secretary | Sell | 1,758 | $226.88 |
The table shows open-market purchases and sales reported over the past 90 days. Directors, officers and shareholders owning more than ten percent must report such transactions within two trading days. Awards and option exercises are excluded.
“Plan” means the transaction follows a schedule set up in advance under Rule 10b5-1. Sales consistently outnumber purchases in these filings because a large part of executive pay is granted in shares. For comparison: over the period covered, executives and directors reported sales at 271 of 350 tracked companies and purchases at 32.
Stocks With ETF Exposure Similar to Alnylam Pharmaceuticals Inc
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | – | – | -63.3% | 48.0% | 8.4% | +65.2% |
| Neurocrine Biosciences | 17 | – | +5.8% | 36.2% | 16.7% | +21.4% |
 Amgen | 21 | – | +59.6% | 27.7% | 21.0% | +10.0% |
 Vertex Pharmaceuticals Incorporated | 21 | – | +33.1% | 31.8% | 32.9% | +8.9% |
 Regeneron Pharmaceuticals | 20 | – | +41.9% | 36.5% | 31.4% | +1.0% |
 Gilead Sciences | 21 | – | +44.1% | 26.8% | 28.9% | +2.4% |
 IDEXX Laboratories | 20 | – | -12.3% | 36.6% | 24.6% | +10.4% |
 Insmed Incorporated | 16 | – | -42.0% | 54.9% | -210.5% | +66.7% |
 Medline | 16 | – | – | 43.8% | 4.1% | +11.5% |
These stocks reach a portfolio through largely the same funds as Alnylam Pharmaceuticals Inc. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Dec 2023 | 1.8 | -0.4 | -24.1% |
| FY ended Dec 2024 | 2.2 | -0.3 | -12.4% |
| FY ended Dec 2025 | 3.7 | 0.3 | 8.4% |
Technical Analysis: Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Risk Metrics
The close on Oct 30, 2026, was 66.4% below the highest close since Aug 12, 2024. That high was reached on Oct 20, 2025. When the S&P 500 rose or fell 1%, Alnylam Pharmaceuticals Inc moved 0.54% on average in the same direction (past 252 trading days). The correlation of 0.13, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Alnylam Pharmaceuticals Inc.
What Alnylam Pharmaceuticals Inc Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| Haleon plc | +0.55 | |
| Rentokil Initial plc | +0.48 | |
| ServiceNow Inc. | +0.48 | |
| Alphabet Inc. Class A | +0.42 | |
| Alphabet Inc. Class C | +0.40 | |
| ACH | +0.40 | |
| Huntington Ingalls Industries Inc. | -0.63 | |
| HYPE | -0.54 | |
| Quanta Services Inc. | -0.46 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
